From Assay to Asset: How End‑to‑End Companion Diagnostic Partnerships Deliver Strategic Platform Selection, Clinical Development Alignment, & Reliable Execution

2:10 pm - Wednesday 7th October 2026

  • Essential attributes of a high‑performing CDx
  • Executing complex, multi‑stakeholder CDx programs
  • How CDx experience accelerates market, regulatory, and clinical success

Speakers:

Associate Director, Business Development, Companion Diagnostics
Abbott Laboratories
Director II, Companion Diagnostics Strategy Team Lead
AbbVie
Program Manager
Abbott Laboratories
Director, R&D
Abbott Molecular